Bank of New York Mellon
LBPH

Bank of New York Mellon’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Bank of New York Mellon’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-74,377
Closed -$2.48M – 4215
2024
Q3 		$2.48M Sell
74,377
-18,287
-20% -$630K ﹤0.01% 2648
2024
Q2 		$2.5M Buy
92,664
+23,774
+35% +$469K ﹤0.01% 2669
2024
Q1 		$1.49M Buy
68,890
+23,138
+51% +$505K ﹤0.01% 2927
2023
Q4 		$276K Hold
45,752
– – ﹤0.01% 3833
2023
Q3 		$254K Hold
45,752
– – ﹤0.01% 3878
2023
Q2 		$336K Buy
+45,752
New +$346K ﹤0.01% 3782

Bank of New York Mellon's LBPH Position: Q4 2024 in Review

Bank of New York Mellon sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 74,377 shares — an estimated $2.48M sold.

Bank of New York Mellon first reported a position in LBPH in Q2 2023 and held it in 6 quarters. The position peaked at $2.5M in Q2 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

  • Bank of New York Mellon reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 74,377 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $2.48M.
  • Bank of New York Mellon first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 6 quarters.
  • Bank of New York Mellon's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $2.5M in Q2 2024.
  • 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Bank of New York Mellon's 13F filing for Q4 2024, filed 4 Feb 2025.